Objectives: To evaluate the feasibility and safety of minimally invasive enucleation of benign esophageal leiomyomas at K Hospital.
Methods: A retrospective descriptive study was conducted on all 24 consecutive patients with pathologically confirmed esophageal leiomyoma treated at the Department of Gastrointestinal Surgery II, K Hospital, from January 2019 to June 2025.
Results: The mean age was 48.5 ± 12.3 years (range 24–68); 70.8% were male. Clinical symptoms were present in 87.5% of patients, dysphagia (75.0%) and chest pain (12.5%), while 12.5% were asymptomatic. Tumors were predominantly in the middle (62.5%) and lower (33.3%) thirds of the esophagus, with a mean diameter of 33.6 ± 17.4 mm (range 8–80 mm). A right thoracoscopic approach was used in 91.7% and a transabdominal laparoscopic approach in 8.3% of cases. No intraoperative complications were recorded. Mean operative times were 83.9 ± 17.0 min (thoracoscopic) and 140.0 ± 14.1 min (laparoscopic). One patient (4.2%) developed postoperative pneumonia. Mean hospital stay was 7.12 ± 1.1 days.
Conclusion: In this series of 24 patients, minimally invasive esophageal leiomyoma enucleation at K Hospital was feasible and safe, with no intraoperative complications and a low rate of early postoperative morbidity.